Long-term Results of Intravesical Hyaluronan Therapy in Bladder Pain Syndrome/interstitial Cystitis

Overview

Journal Int Urogynecol J

Publisher Springer

Specialties Gynecology & Obstetrics
Urology

Date 2010 Oct 13

PMID 20938644

Citations 36

Authors

Paul F Engelhardt

Nike Morakis

Lukas K Daha

Britta Esterbauer

Claus R Riedl

Affiliations

Soon will be listed here.

Abstract

Introduction And Hypothesis: While the short-term efficacy of intravesical hyaluronan for bladder pain syndrome/interstitial cystitis (BPS/IC) has been demonstrated, no data exist on the long-term outcome of this therapy.

Methods: Seventy BPS/IC patients treated with intravesical hyaluronan therapy from 2001 to 2003 were asked to rate their present status of bladder symptoms on a visual analog scale.

Results: Forty-eight of 70 patients responded after a mean follow-up of 4.9 years. The average initial VAS score of 8.15 had been reduced to 2.71 after therapy and further to 2.14 5 years later. Fifty percent of patients (24/48) reported complete bladder symptom remission at 5 years follow-up without any additional therapy; 41.7% (20/48) with symptom recurrence was improved with hyaluronan maintenance therapy. No improvement was reported by four patients.

Conclusions: Besides a high rate of acute symptom remission, intravesical hyaluronan also shows long-term efficacy in a considerable number of BPS/IC patients.

Citing Articles

Intravesical Instillations of Hyaluronic Acid as First-Line Treatment in Patients with Interstitial Cystitis/Bladder Pain Syndrome: Use, Efficacy and Effects on Quality of Life.

Plotti F, Cundari G, Ficarola F, Terranova C, De Cicco Nardone C, Montera R Healthcare (Basel). 2024; 12(12).

PMID: 38921303 PMC: 11203325. DOI: 10.3390/healthcare12121190.

The Model of Interstitial Cystitis for Evaluating New Molecular Strategies of Interstitial Regeneration in Humans.

Mormone E, Cisternino A, Capone L, Caradonna E, Sbarbati A Int J Mol Sci. 2024; 25(4).

PMID: 38397003 PMC: 10889234. DOI: 10.3390/ijms25042326.

Current Understanding of the Pathophysiology and Novel Treatments of Interstitial Cystitis/Bladder Pain Syndrome.

Jhang J, Jiang Y, Kuo H Biomedicines. 2022; 10(10).

PMID: 36289642 PMC: 9598807. DOI: 10.3390/biomedicines10102380.

Changes in Cystoscopic Findings after Intravesical Hyaluronic Acid Instillation Therapy in Patients with Interstitial Cystitis.

Lin C, Liu C, Hsieh H, Chen M, Tsai C Diagnostics (Basel). 2022; 12(8).

PMID: 36010358 PMC: 9407291. DOI: 10.3390/diagnostics12082009.

Urinary Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome and Its Impact on Therapeutic Outcome.

Lin H, Lu J, Chuang S, Chueh K, Juan T, Liu Y Diagnostics (Basel). 2022; 12(1).

PMID: 35054241 PMC: 8774507. DOI: 10.3390/diagnostics12010075.

References

Steinhoff G, Ittah B, Rowan S . The efficacy of chondroitin sulfate 0.2% in treating interstitial cystitis. Can J Urol. 2002; 9(1):1454-8. View

Porru D, Campus G, Tudino D, Valdes E, Vespa A, Scarpa R . Results of treatment of refractory interstitial cystitis with intravesical hyaluronic acid. Urol Int. 1997; 59(1):26-9. DOI: 10.1159/000283012. View

Fall M, Oberpenning F, Peeker R . Treatment of bladder pain syndrome/interstitial cystitis 2008: can we make evidence-based decisions?. Eur Urol. 2008; 54(1):65-75. DOI: 10.1016/j.eururo.2008.03.086. View

Morales A, Emerson L, Nickel J, Lundie M . Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. J Urol. 1996; 156(1):45-8. View

Nickel J, Egerdie B, Downey J, Singh R, Skehan A, Carr L . A real-life multicentre clinical practice study to evaluate the efficacy and safety of intravesical chondroitin sulphate for the treatment of interstitial cystitis. BJU Int. 2008; 103(1):56-60. DOI: 10.1111/j.1464-410X.2008.08028.x. View

Schulz A, Vestweber A, Dressler D . [Anti-inflammatory action of a hyaluronic acid-chondroitin sulfate preparation in an in vitro bladder model]. Aktuelle Urol. 2009; 40(2):109-12. DOI: 10.1055/s-0028-1098784. View

Teichman J . Potassium leak test predicts outcome in interstitial cystitis. J Urol. 1999; 161(6):1791-4; discussion 1794-6. View

Kallestrup E, Jorgensen S, Nordling J, Hald T . Treatment of interstitial cystitis with Cystistat: a hyaluronic acid product. Scand J Urol Nephrol. 2005; 39(2):143-7. DOI: 10.1080/00365590410015876-1. View

Parsons C, Housley T, Schmidt J, Lebow D . Treatment of interstitial cystitis with intravesical heparin. Br J Urol. 1994; 73(5):504-7. DOI: 10.1111/j.1464-410x.1994.tb07634.x. View

10.

Lowell Parsons C, Forrest J, Nickel J, Evans R, Lloyd L, Barkin J . Effect of pentosan polysulfate therapy on intravesical potassium sensitivity. Urology. 2002; 59(3):329-33. DOI: 10.1016/s0090-4295(01)01586-2. View

11.

Bade J, Laseur M, Nieuwenburg A, van der Weele L, Mensink H . A placebo-controlled study of intravesical pentosanpolysulphate for the treatment of interstitial cystitis. Br J Urol. 1997; 79(2):168-71. DOI: 10.1046/j.1464-410x.1997.03384.x. View

12.

Daha L, Riedl C, Hohlbrugger G, Knoll M, Engelhardt P, Pfluger H . Comparative assessment of maximal bladder capacity, 0.9% NaCl versus 0.2 M Kcl, for the diagnosis of interstitial cystitis: a prospective controlled study. J Urol. 2003; 170(3):807-9. DOI: 10.1097/01.ju.0000081163.46167.82. View

13.

Riedl C, Engelhardt P, Daha K, Morakis N, Pfluger H . Hyaluronan treatment of interstitial cystitis/painful bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct. 2007; 19(5):717-21. DOI: 10.1007/s00192-007-0515-5. View

14.

Daha L, Riedl C, Lazar D, Simak R, Pfluger H . Effect of intravesical glycosaminoglycan substitution therapy on bladder pain syndrome/interstitial cystitis, bladder capacity and potassium sensitivity. Scand J Urol Nephrol. 2009; 42(4):369-72. DOI: 10.1080/00365590701871518. View

15.

Hurst R . Structure, function, and pathology of proteoglycans and glycosaminoglycans in the urinary tract. World J Urol. 1994; 12(1):3-10. DOI: 10.1007/BF00182044. View

16.

Gupta S, Pidcock L, Parr N . The potassium sensitivity test: a predictor of treatment response in interstitial cystitis. BJU Int. 2005; 96(7):1063-6. DOI: 10.1111/j.1464-410X.2005.05776.x. View

17.

Toft B, Nordling J . Recent developments of intravesical therapy of painful bladder syndrome/interstitial cystitis: a review. Curr Opin Urol. 2006; 16(4):268-72. DOI: 10.1097/01.mou.0000232048.81965.16. View

18.

Leppilahti M, Hellstrom P, Tammela T . Effect of diagnostic hydrodistension and four intravesical hyaluronic acid instillations on bladder ICAM-1 intensity and association of ICAM-1 intensity with clinical response in patients with interstitial cystitis. Urology. 2002; 60(1):46-51. DOI: 10.1016/s0090-4295(02)01613-8. View